Exscientia Announces Closing of Global Funding of $ 510.4 Million, Consisting of $ 350.4 Million Initial Public Offering with Full Exercise of Underwriters’ Option to Purchase Additional ADS and a concurrent private placement of $ 160.0 million



OXFORD, England – (COMMERCIAL THREAD) – Exscientia plc (Nasdaq: EXAI), an AI-driven pharmaceutical technology company committed to discovering, designing and developing the best possible drugs in the fastest and most efficient way, announced today hui the closing of its initial public offering in the United States of 15,927,500 American Depositary Shares (“ADS”) representing 15,927,500 ordinary shares, of which 2,077,500 ADS were sold under the full exercise of the year. option previously granted to the Underwriters to purchase additional ADSs. All ADSs sold under the offering were offered by Exscientia at a public offering price of $ 22.00 per ADS. The aggregate gross proceeds of the Offering for Exscientia were approximately $ 350.4 million, before the deduction of sales rebates and commissions and the estimated offering fees payable by Exscientia. The offering was increased by the number of shares offered at launch and listed at the top of the price range indicated at launch.

The Company also completed the simultaneous sale of an additional 7,272,727 ADS at a price of $ 22.00 per ADS, for gross proceeds of $ 160.0 million, before deduction of subscription discounts and commissions payable by Exscientia, in in connection with simultaneous private placements with SVF II Excel (DE) LLC. , or Softbank, and the Bill & Melinda Gates Foundation.

Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, BofA Securities and Barclays Capital Inc. acted as co-book managers for the offering.

A registration statement relating to these securities was declared effective by the United States Securities and Exchange Commission (the “SEC”) on September 30, 2021. This press release does not constitute an offer to sell or the solicitation of an offer to purchase securities, and does not constitute an offer, solicitation or sale in any jurisdiction in which such an offer, solicitation or sale would be illegal prior to registration or qualification under securities laws of this jurisdiction.

The offer was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from one of the co-book managers for the offering: Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 866-471-2526, fax: 212-902-9316, e-mail: [email protected]; Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by phone at 866-718-1649 or by email at [email protected]; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or e-mail: [email protected]; or Barclays Capital Inc., c / o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by phone at 1-888-603-5847 or by email at [email protected] For the avoidance of doubt, this prospectus will not constitute a “prospectus” for the purposes of Regulation (EU) 2017/1129 and has not been reviewed by any competent authority of a Member State of the European Economic Area or of the United Kingdom. -United.

In any member state of the European Economic Area (the “EEA”), this announcement and any offer are directed and directed only to persons who are “Qualified Investors” (“Qualified Investors”) at meaning of the Prospectus Regulation (Regulation (EU) 2017/1129). In the United Kingdom, this announcement and any offer are intended and directed only to persons who are “qualified investors” within the meaning of the United Kingdom Prospectus Regulation (Regulation (EU) 2017/1129 as if they were part of national law under the European Union (Withdrawal) Act 2018) (i) who have professional experience in investment matters falling under Article 19 (5) of the 2000 Act on Financial Services and Markets (Financial Promotion) 2005, as amended (the “Ordinance”), (ii) High Net Worth Entities falling under section 49 (2) (a) to (d) of the Ordinance, or (iii) to whom it may be legally communicated (all such persons being referred to as “persons”).

This advertisement must not be used or relied on (i) in the United Kingdom, by persons who are not Data Subjects, and (ii) in an EEA Member State, by persons who are not investors qualified. Any investment or investment activity to which this announcement relates is only available and will only be undertaken with (i) in the UK, relevant persons, and (ii) in any EEA Member State, qualified investors .

About Exscientia

Exscientia is an AI-driven pharmaceutical company committed to discovering, designing and developing the best possible drugs in the fastest and most efficient way. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to advance AI-designed small molecules in the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precisely designed therapeutic candidates, with more than 25 projects underway, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.


Leave A Reply

Your email address will not be published.